Last update Feb. 10, 2019


Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Antibiotic of the quinolone type, active in vitro against Pseudomonas aeruginosa, structurally related to nalidixic acid.
It has been used orally and intravenously (two daily doses) to treat urinary tract infections from Gram-negative bacteria (Shimizu M 1975).

SInce the last update we have not found published data on its excretion in breastmilk.

Low toxicity in humans has been reported (Azierta 2016).

This product has very few bibliographical references.

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity or glucose-6-phosphate dehydrogenase deficiency.

The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to alteration of the intestinal flora (Ito 1993).

See below the information of this related product:

  • Nalidixic Acid (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)


  • Ciprofloxacin (Safe substance and/or breastfeeding is the best option.)
  • Norfloxacin (Safe substance and/or breastfeeding is the best option.)
  • Ofloxacin (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

J01MB04 is Pipemidic Acid in ATC Code/s.

Is written in other languages:

J01MB04 is also known as


J01MB04 belongs to this group or family:


Main tradenames from several countries containing J01MB04 in its composition:


Variable Value Unit
Oral Bioavail. 93 %
Molecular weight 303 daltons
Protein Binding 39 %
VD 1.7 l/Kg
Tmax 1.1 hours
3.5 hours


  1. Azierta. Pipemidic acid. Drug Summary. 2016 Full text (in our servers)
  2. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  3. Klinge E, Männistö PT, Mäntylä R, Mattila J, Hänninen U. Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. Antimicrob Agents Chemother. 1984 Abstract
  4. Shimizu M, Nakamura S, Takase Y, Kurobe N. Pipemidic acid: absorption, distribution, and excretion. Antimicrob Agents Chemother. 1975 Abstract
  5. Shimizu M, Takase Y, Nakamura S, Katae H, Minami A. Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties. Antimicrob Agents Chemother. 1975 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM